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ABSTRACT
PNRC and PNRC2 are members of a new family of
nuclear receptor coactivators. We systematically
determined the molecular basis and the structure/
function relationship for the PNRC–ERa interaction.
PNRC was found to interact with ERa mainly
through its C-terminus region, amino acids 270–
327, and an SH3-binding motif within this region
was shown to be essential for PNRC to interact with
and function as coactivator of ERa. The importance
of the flanking sequences of SH3-binding motif in
the interaction between PNRC and ERa was also
investigated. The PNRC-interacting domain(s) on
ERa was also mapped. PNRC was found to interact
with both AF1 and LBD of ERa, and to function as a
coactivator for both AF1 and AF2 transactivation
functions. The interaction of ERa mutants, I358R,
K362A, V376R, L539R and E542K, with PNRC/PNRC2
was further investigated. ERa/HBD/V376R could
bind to PNRC or PNRC2, with similar affinity as
wild-type ERa/HBD, and the transactivation activity
of ERa/V376R was enhanced 5-fold by PNRC. Since
GRIP1, a well-characterized coactivator, was found
not to be able to enhance the transactivation
function of this mutant, our results indicate that
the PNRC–ERa interaction interface is not exactly
identical to that of GRIP1–ERa interaction.
INTRODUCTION
Nuclear receptor-mediated signaling is an important regula-
tory pathway in breast tissue. Estrogen and progesterone are
critical hormones that regulate normal mammary gland devel-
opment during puberty and pregnancy, and are associated
with the initiation, development and progression of breast
cancer (1,2). These hormones function via binding to their
corresponding nuclear receptors, ER and PR. Ligand-bound
nuclear receptors are transcriptional factors that regulate the
expression of various genes by binding to the speciﬁc
hormone-responsive elements located in the target gene pro-
moters, thus playing essential roles in development, differen-
tiation, cell proliferation and metabolism. For the past few
years, a great deal of progress has been made in understand-
ing the mechanisms by which the nuclear receptors regulate
gene transcription. The function of nuclear receptors can be
regulated by a number of factors including ligand binding,
DNA binding, interaction with other members in the family,
interaction with basal transcription factors, and interaction
with coactivators and corepressors. Most of these coactivators
of nuclear receptors have molecular weights of  160 kDa
and interact with the liganded nuclear receptors using a
short hydrophobic motif called NR-box or LXXLL-motif
(3,4).
During the studies of mechanisms that regulate the expres-
sion of the human aromatase gene in breast cancer, we have
identiﬁed and characterized a new family of coactivator pro-
teins, PNRC (proline-rich nuclear receptor coregulatory pro-
tein) (5) and PNRC2 (6). PNRC and PNRC2 were identiﬁed
as SF-1 (steroidogenic factor 1)-interacting proteins in a yeast
two-hybrid screening of a human mammary gland cDNA
expression library. These coactivators are unique in that
they are signiﬁcantly smaller than most of the coregulatory
proteins previously identiﬁed and are proline-rich. We have
found that PNRC and PNRC2 interact with the ligand-
binding domains of all the nuclear receptors tested, including
ER, PR, GR, TR, RAR and RXR, in a ligand-dependent man-
ner. They were also found to interact in a ligand-independent
manner with the orphan receptors SF1 and estrogen receptor-
related receptor alpha (ERRa). Recently, PNRC2 was also
isolated from a human brain cDNA phage display library
by its interaction with the AF1 domain of ERRg (7). Further-
more, through an automated yeast two-hybrid screening
method to identify nuclear receptor-interacting proteins (8),
PNRC was found to interact with RARb, RARg, RORa,
RORb, HNF4a, HNF4g,E R b, ERRg and LRH1, and
PNRC2 was found to interact with RARg, RORa, RORb,
HNF4a, HNF4g,E R a,E R b, ERRg and LRH1. These authors
*To whom correspondence should be addressed. Tel: +1 626 359 8111, ext. 63454; Fax: +1 626 301 8972; Email: schen@coh.org
  2006 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
5974–5986 Nucleic Acids Research, 2006, Vol. 34, No. 20 Published online 26 October 2006
doi:10.1093/nar/gkl764state that PNRC2 (and PNRC) appears to be a more general
cofactor for nuclear receptor than previously appreciated.
Unlike most of the coactivators that interact with nuclear
receptors through their LXXLL motif, PNRC and PNRC2
interact with nuclear receptors mainly through a proline-
rich Src homology domain-3 (SH3)-binding motif, S-D
(E)-P-P-S-P-S (5,6). In addition to interacting with nuclear
receptor and functioning as coactivator, PNRC also interacts
with SH3-domains of Grb2 through its two SH3-binding
motifs, located at its N-terminus and C-terminus, and
down-regulates the activation of Ras and MAP kinase (9).
Therefore, PNRC modulates both nuclear receptor-mediated
pathways and growth factor-mediated pathways.
The molecular basis of the interaction between ERa and a
number of coactivators has been extensively investigated
(10–17). As summarized above, our previous studies indicate
that PNRC is a novel coactivator protein. In this study, we
carried out a systemic analysis to determine the key regions
in PNRC and ERa for their interaction and function. We
believe that such information will help us understand better
the regulatory function of PNRC on the activity of ERa
that plays a very important role in normal mammary gland
and breast cancer development.
MATERIALS AND METHODS
Cell lines and reagents
HeLa cells, human epithelial cells derived from a cervical
carcinoma, were purchased from ATCC and were grown in
Earle’s MEM supplemented with 10% fetal bovine serum
(FBS), 100 U of penicillin per ml, 100 mg of streptomycin
per ml and nonessential amino acid and sodium pyruvate.
The MATCHMAKER Two-Hybrid System kit was pur-
chased from Clontech (Palo Alto, CA). Yeast transformation
kit was purchased from Bio 101 (La Jolla, CA), and the yeast
culture media were purchased from Clontech. Various restric-
tion endonuclease were purchased from New England
Biolabs (Beverly, MA). Hot start Taq polymerase was
purchased from Qiagen (Valencia, CA). Lipofectamine
2000 was purchased from Invitrogen Corporation (Carlsbad,
CA). Mouse ER antibody was purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). PNRC antiserum
was generated from our laboratory (9). Luciferase assay sys-
tem was purchased from Promega Corporation (Madison,
WI). TNT Quick Coupled Transcription/Translation System
was purchased from Promega Corporation (Madison, WI).
Bug Buster GST-bind puriﬁcation kit was purchased from
Novagen Inc. (Madison, WI). Oligonucleotide primers were
synthesized in the DNA/RNA chemistry laboratory at the
City of Hope. DNA sequencing was done in City of Hope
Sequencing Core facility.
Construction of plasmids
All recombinant DNA and plasmid constructions were pre-
pared according to standard procedures, and the sequences
and orientations of inserted DNA fragments in plasmid
constructs were veriﬁed by standard DNA sequencing.
Yeast expression plasmids in pACT2 vector for the fusion
proteins of ADGal4 and PNRC or PNRC2 fragments including
ADGal4–PNRC1–327,ADGal4–PNRC96–327,AD Gal4–PNRC102–327,
ADGal4–PNRC120–327,A D Gal4–PNRC157–327,A D Gal4–
PNRC167–327,A D Gal4–PNRC184–327,A D Gal4–PNRC243–327,
ADGal4–PNRC263–327,A D Gal4–PNRC277–327 and ADGal4–
PNRC270–327 (used in Figure 1) or ADGal4–PNRC25–139,
ADGal4–PNRC212–139,A D Gal4–PNRC245–139,A D Gal4–
PNRC285–139 and ADGal4–PNRC2110–139 (used in Figure 3)
were isolated from yeast two-hybrid screening of human
mammary gland cDNA library using bovine SF1 as bait (4).
To test the importance of NR box sequence, LKTLL, located
in amino acid residues 319–323, the plasmid pACT2–
PNRC270–327/del319–323 (deletion of NR box) was prepared
by inserting the PCR-ampliﬁed PNRC270–327/del319–323-
coding region into pACT2 vector through the EcoR1 and
Xho1 sites. The sequences of primers for amplifying the
PNRC270–327/del319–323-coding region are 50-GCC GAATTC
GA CTA ACT GAA GTG AGC CAA AAG-30 and 50-CGG
CTCGAG CTA AGT TTG AAC TTT GAA GAG-30.T o
examine the importance of sequences of SH3-binding motif,
SDPPSPS, located in amino acids region 285–291 of PNRC, a
modiﬁed QuikChange site-directed mutagenesis (Stratagene)
method was used to introduce internal deletion (18). Two pri-
mers, 50-AA AAG GAA AAT TAT GCT GGG GCA AAG
TTT GTT CTT CCA AAG CCT CCT A-30 and 50-CCA
GTG ACT AGG AGG CTT TGG AAG AAC AAA CTT
TGC CCC AGC ATA ATT-30, were used in PCR to amplify
the coding region for PNRC270–327/del285–319 (deletion of
SH3-binding motif) and the PCR product was inserted into
pACT2 vector through EcoR1 and Xho1 sites. To examine
the importance of the ﬂanking sequences of SH3-binding
motif, amino acid residues 270–284, in the interaction
between PNRC and ERa, the amino acid region 270–284
was either deleted by generating the plasmid pACT2–
PNRC285–327 or replaced with PNRC285–98 in the plasmid
pACT2 PNRC285–98/PNRC285–327. To construct pACT2–
PNRC285–327, the coding region for PNRC285–327 was gener-
ated by PCR and inserted into pACT2 vector through EcoR1
and Xho1 sites. To prepare the pACT2–PNRC285–98/
PNRC285–327, the coding region for PNRC285–98 was ﬁrst
ampliﬁed by PCR with primers 50-GAG GCC CCG GGG
ATC CGA ATT CGA TTT AAA TCT CAA GCT AAT
CAG-30 and 50-AAC ACT AGG AGA AGG TGG ATC
ACT AAA TTT GGC ACC AGC ATA GTT-30 and inserted
into the N-terminal of PNRC285–327 in pACT2–PNRC285–327
vector using an adaptation of the QuikChange mutagenesis
approach (19). To examine the importance of the region
between SH3-binding motif and NR box, amino acid residues
292–318, in the PNRC–ERa interaction, the region 292–318
was either deleted as in pACT2–PNRC270–327/del282–318 or
replaced with PNRC2106–131 as in the pACT2–PNRC270–291/
PNRC2106–131/PNRC319–327. The pACT2–PNRC270–327/
del292–318 was prepared by QuikChange mutagenesis method
with two complementary mutagenic oligonucleotide primers:
50-CA AAG TTT AGT GAT CCA CCT TCT CCT AGT TTA
AAA ACC CTC CTC AAA G-30 and 50-AGT TTG AAC TTT
GAG GAG GGT TTT TAA ACT AGG AGA AGG TGG
ATC ACT-30. These two mutagenic oligonucleotides were
also used in another PCR mutagenesis reaction using pCI–
PNRC as template to generate pCI–PNRC/del292–318 con-
struct. This construct was used in transient transfection to
examine whether the PNRC292–318 region is required for its
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Figure 1. PNRC interacts with ERa through its C-terminus. (A) Interaction between mERa/HBD and PNRC or PNRC fragments in yeast two-hybrid assays.
The expression plasmids (in pACT2 vector) for ADGal4 and PNRC fragment fusion proteins were isolated from a human mammary gland expression
library screening using DBDGal4–SF1 (in pGBT9 vector) as bait (5). Yeast strain Y187 was cotransformed with pGBT9–mERa/HBD (for the expression of
DBDGal4–mERa/HBD fusion protein) and each of the expression plasmids for ADGal4–PNRC fragments as indicated, and transformants containing these
plasmids were selected by growth on SD/ Leu/ Trp agar plates. The expression of interacting hybrid proteins in Y187 transformants was analyzed for LacZ
expression as described in Materials and Methods. ADGal4 (AD) was included as background control. b-Galactosidase activities in liquid cultures in the presence
of 17-b-estradiol (10 nM) are expressed in Miller units as mean ± SD of three independent assays. (B) Direct binding between ERa and PNRC in GST pull-down
assay. Binding of
35S-labeled ERa with GST (lanes 2 and 3), GST–PNRC270–327 (lanes 4 and 5) and GST–PNRC278–300 (lanes 6 and 7) was tested using the pull-
down assay in the presence of 10 nM E2 or DMSO (the vehicle control). The input (lane 1) represents 10% of the labeled ERa used in each reaction. The bound
35S-ERa was detected by autoradiography (upper panel). One-third of GST proteins eluted from pull-down reaction are shown by Coomassie blue stain at the
lower panel.
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binding motif and NR box sequence in the coactivation func-
tion of PNRC, pCI–PNRC/del SH3 motif and pCI–PNRC/del
NR box were generated by QuickChange Mutagenesis
approach on pCI–PNRC template using the mutagenic pri-
mers mentioned above. To examine the cellular localization
of PNRC/del SH3-binding motif, the coding region for
PNRC/del SH3-binding motif was ampliﬁed by PCR on
pCI–PNRC/del SH3-binding motif plasmid template, and
the PCR product was subcloned in frame into pEGFP-C1 vec-
tor (Clontech) through HindIII and Xba1 sites.
To generate the plasmid pACT2–PNRC270–291/
PNRC2106–131/PNRC319–327, the coding region for
PNRC2106–130 was ﬁrst ampliﬁed by PCR using pBluescript-
PNRC2 as template and primer set: 50-AGT GAT CCA CCT
TCT CCT AGT GTT CTT CCC AAA CCA CCA AGC-30
and 50-G AAC TTT GAG GAG GGT TTT TAA TTG
AAA TGT CAT TAT TTC CTT ATC-30. The 50 end of
one of the two oligonucleotides used for the PCR was
designed by having at least 20 nt corresponding exactly to
the DNA sequence upstream from the point of insertion in
the destination vector, followed by the ﬁrst 20 nt of the
DNA fragment to be ampliﬁed. Accordingly, the 50 end of
the other oligonucleotide consisted of at least 20 nt exactly
downstream from the point of insertion, followed by the
last 20 nt of the target DNA fragment. The latter oligonu-
cleotide was derived from the complementary DNA strand.
After PCR, the PCR product was separated on agarose gel
and puriﬁed. The insertion of this PCR product, PNRC2106–130,
into pACT2–PNRC270–327 to replace PNRC292–318 was
achieved by QuikChange Mutagenesis PCR using pACT2–
PNRC270–327 as template and the PCR product, in this
case, PNRC2106–130.
All the PCR mutagenesis reactions were performed in a
reaction volume of 50 ml that consisted of 100–500 ng of tem-
plate plasmid DNA, 200 nM each primer or 200–300 ng of
PCR fragment (for insertion and replacement), 200 mM
dNTPs, 2.5 U Pfu enzyme in 1· Pfu DNA polymerase reac-
tion buffer. A preliminary step of denaturation at 95 C for
3 min was followed by 25 cycles of PCR. These PCR cycles
consisted of 30 s of denaturation at 95 C, 1 min of annealing
at a temperature 2 C higher than melting temperature (Tm)o f
the primer and 2 min/kb template plasmid DNA of extension
at 68 C. At the end of PCR, the PCR product was treated with
10 U Dpn1 for 3 h at 37 C and 2 ml of Dpn1-digested DNA
was transformed into DH5a-competent cells using electropo-
ration. The construction of the plasmids for the expression of
ADGal4–PNRC270–317 (with deletion of last 10 amino acid that
contains NR box sequence), ADGal4–PNRC278–300 (contains
SH3-binding motif), ADGal4–PNRC278–300/2P>2A (mutated
SH3-binding motif), ADGal4–PNRC301–327 (deletion of
SH3-binding motif containing region) and ADGal4–
PNRCNR box, were previously described (5).
The mammalian expression plasmids for mutated ERa in
pSG5 vectors, including pSG5–ERa/I358R, pSG5–ERa/
V376R, pSG5–ERa/L539R, pSG5–ERa/K362A and pSG5–
ERa/E542K, were generated by QuikChange Site-directed
mutagenesis method on pSG5–ERa template plasmid using
following primers:
The yeast expression plasmids for the fusion proteins of
DBDGal4 and ERa/HBD297–554 or mutated ERa/HBD
including ERa/HBD/I358R, ERa/HBD/V376R, ERa/HBD/
L539R, ERa/HBD/K362A and ERa/HBD/E542K were pre-
pared as follows. The coding regions for wild-type ERa/
HBD and mutated ERa/HBD were PCR-ampliﬁed using for-
ward primer, 50-GCG GAATTC ATG ATC AAA CGC TCT
AAG AAG-30 and reverse primer, 50-GAA GGATCC TCA
GCT AGT GGG CGC ATG TAG-30 and pSG5–ERa/WT
and corresponding ERa mutation containing plasmids as tem-
plates, respectively. The PCR products were then digested
with EcoR1 and BamH1, and subcloned into pGBT9 vector
through EcoR1 and BamH1 sites.
The deletion fragments of ERa, including ERa/1–185
(AF1), ERa/185–251 (DBD), ERa/252–355 (Hinge), ERa/
356–549 (HBD), ERa/550–595 (F domain) and ERa/252–
288 (CTE domain) were PCR-ampliﬁed from pSG5–ERa
with the primers incorporating EcoR1 at the 50 ends and
BamH1 at the 30 ends, and inserted into pGBT9 vector. The
ERa fragments, ERa/1–549, ERa/185–595, and ERa/1–251,
were PCR-ampliﬁed with the primers incorporating EcoR1
and BamH1 sites, and inserted into the mammalian expres-
sion vector pSG5.
Yeast two-hybrid assay
The yeast MATCHMAKER two-hybrid system (Clontech)
was used to examine protein–protein interaction in vivo.
Brieﬂy, the yeast strain Y187 was co-transformed with the
AD vector alone or AD–PNRC wild-type or its fragments
along with pGBT9 (DBDGal4 vector only), pGBT9–ERa/
HBD or mutated ERa/HBD plasmids or DBD–hLC negative
control plasmid. The transformants that carry both plasmids
were selected by plating them onto SD/ Leu/ Trp plates
and were further analyzed for b-galactosidase activity by liq-
uid b-galactosidase activity measurement as essentially
described in the protocol. Brieﬂy, the transformants that
grew on SD/ Leu/ Trp agar plates were cultured overnight
in liquid SD/ Leu/ Trp medium at 30 C. This overnight
culture was diluted in liquid YPD and then continued to incu-
bate for 4–6 h in the presence of 17-b-estradiol (E2) (10 nM)
or Dimethyl sulfoxide (DMSO) (vehicle control). At the end
of this incubation, a liquid b-Galactosidase activity assay,
Mutation Forward primer Reverse primer
I358R 50-GAGCTGGTTCACATGCGCAACTGGGCGAAG-30 50-CTTCGCCCAGTTGCGCATGTGAACCAGCTC-30
V376R 50-ACCCTCCATGATCAGCGCCACCTTCTAGAAT-30 50-ATTCTAGAAGGTGGCGCTGATCATGGAGGGT-30
L539R 50-GTGCCCCTCTATGACCGGCTGCTGGAGATG-30 50-CATCTCCAGCAGCCGGTCATAGAGGGGCAC-30
K362A 50-ATGATCAACTGGGCGGCGAGGGTCCAGGC-30 50-GCCTGGCACCCTCGCCGCCCAGTTGATCAT-30
E542K 50-TATGACCTGCTGCTGAAGATGCTGGACGCC-30 50-GGCGTCCAGCATCTTCAGCAGCAGGTCATA-30
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substrate, was performed according to the manufacturer’s
protocol (Clontech).
Cell culture, transfection and luciferase assays
HeLa cells, a human cervical carcinoma cell line, were cul-
tured in MEM Earle’s Salts medium and supplemented
with 5% charcoal dextran-treated fetal bovine serum (CD-
FBS). Twenty-four hours before transfection, cells were
seeded in 6-well plates at 5 · 10
4/per well. Each well of
cells were transfected with 2.0 mg of lipofectamine 2000
(Invitrogen) and total 1.25 mg of plasmid DNA in 1 ml
of Opti-MEM containing various amounts of the test plas-
mids as indicated in each experiment and appropriate
amounts of empty vector, pSG5 or pCI, to maintain the
same overall amount of total DNA in all transfections.
After 4 h of incubation with medium containing lipofec-
tamine 2000/DNA, 2 ml of MEM/5% CD-FBS medium
containing 10 nM E2 or DMSO (vehicle control) was
added to each well.
Luciferase activity was assayed 24 h after transfection.
Cell extracts were prepared by lysing the cells with 400 ml
of 1· reporter lysis buffer (Promega). The lysate was cen-
trifuged at 12000 g for 20 s to pellet the cell debris. The
supernatants were transferred to a fresh tube and their protein
concentration was determined using the Bio-Rad protein
assay reagent according to the manufacturer’s protocol. The
luciferase activities in the cell lysates with same amount of
total protein from each well were measured using Luciferase
assay substrate (Promega). Each transfection was performed
in triplicate. When necessary, 20 mg of crude cell lysates
from each transfected reaction were subjected to western
blot analysis to examine the expression levels of various
ER mutants and PNRC deletion forms (described below).
Western blot analysis
The procedures have been previously described (5). Brieﬂy,
the lysis buffer (ice cold, 50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate
and the complete set of protease inhibitor cocktail) was
added to the phosphate-buffered saline (PBS)-washed cells.
After 20 min of incubation on ice, the cells were then
scraped and transferred into Eppendorf tubes, sonicated
and centrifuged at 12000 g at 4 C for 10 min. Twenty-
ﬁve micrograms of cell lysate in the supernatant were ana-
lyzed by 10% SDS–PAGE. The proteins were transferred
onto PVDF membranes under 18 V for 60 min using a
Semi Dry Transfer Cell (Bio-Rad). Membranes were
blocked with 5% non-fat milk in 1· Tris-buffered saline
Tween-20 (TBST) buffer at room temperature for 1 h and
then incubated overnight with mouse monoclonal antibody
against ERa (Santa Cruz, sc-8002, 1:500 dilution) or
1:500 diluted PNRC antiserum. The membrane was then
incubated with 1:5000 diluted goat anti-rabbit (for PNRC)
or anti-mouse (for ERa) horseradish peroxidase conjugate
(Pierce Chemical Co.) at room temperature for 1 h and fol-
lowed by SuperSignal West Pico Chemiluminescent (Pierce)
substrate visualization.
GST pull-down assay
The glutathione S-transferase (GST) pull-down assays were
performed as previously described (5). Brieﬂy, the full-length
ERa coding region in pSG5 vector was translated in vitro in
the presence of [
35S]methionine, using the TNT Coupled
Transcription/Translation System (Promega Corp., Madison,
WI). The construction of expression plasmids for GST–
PNRC270–327 and GST–PNRC278–300 was previously
described (5). GST and GST-deleted PNRC fusion proteins
were prepared using BugBuster GST Bind Puriﬁcation kit
(Novagen, Madison, WI) following the supplier’s instruc-
tions. Brieﬂy, 10 mg of puriﬁed GST, GST–PNRC270–327 or
GST–PNRC278–300 was incubated with 20 ml of settled GST
bind resin for 30 min at room temperature. The washed
beads were incubated for 1 h at 4 C with 4 mlo fin vitro
translated, [
35S]methionine-labeled ERa in a total volume
of 150 ml binding buffer (50 mM KPi, pH 7.4, 100 mM
NaCl, 1 mM MgCl2, 10% glycerol, 0.1% Tween-20, 1.5%
BSA) in the presence of 10 nM E2 or DMSO (the vehicle
control). Beads were collected and washed four times with
binding buffer without BSA. Washed beads were resuspended
in 50 mlo f1 · SDS sample buffer, boiled in water for 5 min
and pelleted brieﬂy in a microfuge. Supernatant (25 ml), along
with 1/10 of input [
35S]-labeled ERa, was then subjected to
8% SDS–PAGE and autoradiography. To control the equal
loading of GST and GST fusion proteins, 15 ml of eluate
was separated on another 8% SDS–PAGE gel, and the gel
was subjected to Coomassie blue staining.
Fluorescence imaging
HeLa cells were cultured in MEM Earle’s Salts medium sup-
plemented with 10% FBS, 1 mM sodium pyruvate, 2 mM
L-glutamine, 100 U/ml of penicillin and 100 U/ml of strepto-
mycin for 24 h. The day before transfection, cells were
divided and cultured in 6-well plate. Cells were then trans-
fected with 2 mg of Lipofectin (Invitrogen) and 2 mgo f
pEGFP–PNRCwt, pEGFP–PNRC/del SH3-binding motif, or
pEGFP-C1 vector (as control). After 4 h transfection, the
medium containing Lipofectin and DNA was discarded, and
the cells were cultured in regular culture medium for HeLa
cells. After 20 h incubation, the ﬂuorescent signal was
detected by an inverted ﬂuorescence microscope, Nikon
Eclipse, TE 2000-S. Standard ﬁlter sets were used for all
imaging. All images were processed using Image-Pro Plus
5.1 software and standard image processing techniques.
RESULTS
PNRC interacts with ERa through its C-terminus
PNRC has been demonstrated previously to interact with
ERa in a ligand-dependent and AF-2-dependent manner by
yeast two-hybrid assay, GST pull-down, and Co-
immunoprecipitation analyses (5). To systematically map
the ERa-interacting domains of PNRC, the interaction
between ERa/HBD and the full-length PNRC or its frag-
ments was analyzed and compared by yeast two-hybrid
assays. A series of PNRC fragments in pACT2 (ADGal4) vec-
tor was isolated from our previous yeast two-hybrid screening
of a human mammary gland cDNA expression library using
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+ and
b-Gal
+ clones isolated from the screening code for the
wild-type PNRC protein or PNRC fragments with different
length of deletion at its N-terminus, with the shortest clone
coding for PNRC277–327. The yeast strain, Y187, was cotrans-
formed with pGBT9–ERa/HBD plasmid along with either
pACT2 vector alone (as background control) or each
pACT2–PNRC/fragment plasmid (test plasmid). The trans-
formants that grew on SD/ Leu/ Trp plates were picked
and cultured in liquid YPD containing 10 nM E2 or DMSO
(vehicle control) to the log phase, and the b-galactosidase
activity of the cultured cells were analyzed by liquid
b-galactosidase activity measurement as described in the
Materials and Methods. As shown in Figure 1A, the shortest
fragment, PNRC277–327, interacted with ERa/HBD with the
same afﬁnity as that of full-length PNRC, suggesting that
PNRC interacts with ERa through its C-terminus. Further-
more, the interaction between ERa and PNRC or its fragment
was detected only in the presence of estradiol (Figure 1A),
demonstrating its ligand dependence.
The C-terminus of PNRC binds to ERa directly as
demonstrated in GST pull-down analysis
To further conﬁrm the interaction between the C-terminus of
PNRC and ERa detected in yeast two-hybrid assays, a GST
pull-down binding assay was performed to study the direct
interaction between
35S-labeled full-length ERa and the
PNRC C-terminal fragments in vitro. PNRC fragments,
including PNRC270–327 and PNRC278–300, were expressed as
fusion protein with GST in Escherichia coli BL21, puriﬁed
with glutathione Sepharose 4B beads, and tested for their
ability to bind in vitro translated [
35S]methionine-labeled
ERa in pull-down assays. As shown in Figure 1B, both
GST–PNRC270–327 and GST–PNRC278–300 were found to
bind ERa in the presence of 10 nM estradiol (E2)
(Figure 1B, lanes 5 and 7). These results demonstrate a direct
binding of PNRC to ERa and the interaction is ligand
dependent, because GST alone or in the absence of E2 (vehi-
cle DMSO) retains only very small amounts of
35S-labeled
ERa (Figure 1B, lanes 2–4 and 6).
PNRC/NR box plays role, but not essential, in the
interaction between PNRC and ERa
A short conserved peptide motif LXXLL (referred to as the
NR box) has been identiﬁed and reported to be necessary
and sufﬁcient to mediate the binding of several coactivators
to liganded nuclear receptors (3). There is one NR box-like
sequence, LKTLL (amino acids 319–323), at the very end
of the C-terminus in PNRC. Our previous deletion and muta-
tion experiments suggested that this NR box was not essential
for PNRC to interact with SF1 (5). To conﬁrm our previous
ﬁnding, a series of PNRC fragments were prepared to exam-
ine their interaction with ERa/HBD in yeast two-hybrid
assays. Compared with PNRC270–327, PNRC270–317 fragment
has a deletion of the last 10 amino acid segment that contains
the NR box. As shown in Figure 2, the interaction intensities,
as expressed by b-Gal activity, between PNRC270–327 or
PNRC270–317 and ERa/HBD are about the same, indicating
that the NR box sequence in PNRC is not essential for the
interaction. We also expressed this NR box as a fusion protein
with ADGal4 domain and tested its interaction with ERa/HBD
in yeast. No interaction was detected between NR box and
ERa/HBD, suggesting again that this NR box sequence is
not responsible for the interaction. However, when the
NR box sequence, amino acids 319–323, was deleted from
PNRC270–327 template (PNRC270–327/del319–323), it resulted in
the reduction of the interaction strength between PNRC270–327
and ERa/HBD (Figure 2). Taken together, these results indi-
catedthatNRboxsequencemayparticipate,butisnotessential
and not sufﬁcient to mediate the binding of PNRC to ERa/
HBD. This conclusion was further supported by the fact that
deletion of NR box sequence from PNRC did not affect the
coactivation activity of PNRC on the transcription mediated
by ERa (Figure 3B).
SH3-binding motif in the amino acid region 278–300
is essential for PNRC to interact with and to function
as a coactivator of ERa
Sequence comparison revealed that there is a 23-amino acid
region with a great homology between PNRC and PNRC2,
and this 23-amino acid sequence is within the C-terminal
fragment, PNRC270–327. Our previous results from deletion
and mutation analysis demonstrated that the SH3-binding
motif in the amino acid region 278–300 is essential for
PNRC to interact with SF1 (5). To test whether this is also
true for the interaction between PNRC and ERa, the interac-
tion between ERa/HBD and PNRC278–300 was examined in
yeast two-hybrid assays. As shown in Figure 3A, this
23-amino acid peptide was found to retain most of the inter-
action of the PNRC270–327 to ERa/HBD. Deletion of amino
acid region 270–300 that contains this 23-amino acid segment
from PNRC270–327 (construct pACT2–PNRC301–327) totally
eliminated the ability of PNRC to interact with ERa/HBD
(Figure 3A). Together, these data demonstrated that the
amino acid region from 278 to 300 in PNRC is critical and
sufﬁcient for interaction with ERa.
Figure 2. NR box sequence plays a role, but not essential, in the interaction
between PNRC and ERa. Yeast strain, Y187, was cotransformed with
pGBT9–mERa/HBD and the expression plasmid for ADGal4 (AD, in pACT2
vector) or an yeast expression plasmid for the fusion proteins of ADGal4 and
various deletion mutants of PNRC as indicated. The yeast transformants
bearing both plasmids were cultured in the absence (DMSO) or presence of
10 nM 17-b-estradiol (E2). b-Galactosidase activities were determined and
expressed as the mean (units) ± SD of three independent colonies.
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(amino acid residues 286–291), in the amino acid region
278–300 of PNRC. Double mutations of P287A and P290A
in the putative SH3-binding motif, i.e. SDPPSPS to SDAP-
SAS, in amino acid region 278–300 of PNRC was found to
completely eliminate the interaction between PNRC278–300
and ERa/HBD (Figure 3A). The importance of SH3-binding
motif in the interaction between PNRC and ERa was also
conﬁrmed by deletion of SH3-binding motif in the content of
PNRC270–327.As shown inFigure 3A,deletion ofSH3-binding
motif, amino acid residues 285–291, from PNRC270–327
completely abolished its interaction with ERa/HBD. These
results clearly demonstrated that the SH3-binding motif is
essential for PNRC to interact with ERa. Consequently, dele-
tionof SH3-bindingmotif, aminoacidresidues 286–291, com-
pletely eliminated the coactivation activity of PNRC on the
transcription mediated by ERa, while the deletion of NR
box motif from PNRC did not affect the coactivation function
(Figure3B),demonstratingacrucialroleofSH3-bindingmotif
in ERa interaction and coactivation function of PNRC. To
rule out the possibility that the difference in coactivation
activities among various PNRCdeleted forms might be due
to the different levels of protein expression, western blot
analysis was performed to examine the protein levels of
PNRC, PNRC/del SH3 motif and PNRC/del NR box in
the transfected HeLa cells. As shown in Figure 3C, PNRC
and its deleted forms were found to be expressed at similar
levels in the transfected HeLa cells, demonstrating that the
changes in the coactivation function among PNRC and its
deletion forms are indeed the consequences of correspond-
ing mutation. To further validate that the loss of coactivator
activity of PNRC/del SH3 motif is due to the loss of inter-
action with ERa, instead of an alteration of cellular
localization, the expression plasmids for EGFP–PNRC
Figure 3. SH3-binding motif within amino acid region 278–300 is essential
for PNRC to interact with ERa and function as coactivator of ERa.( A) Yeast
strain, Y187, was cotransformed with pGBT9–mERa/HBD and the
expression plasmid for ADGal4 (AD, in pACT2 vector) or an yeast expression
plasmid for the fusion proteins of ADGal4 and various deletion mutants of
PNRC as indicated. The yeast transformants bearing both plasmids were
cultured in the absence (data not shown) or presence of 17-b-estradiol (10
nM). b-Galactosidase activities were determined and expressed as the mean
(units) ± SD of three independent colonies. (B) HeLa cells cultured in 6-well
plates were transfected with pGL3(ERE)_SV40_Luciferase reporter (0.25 mg)
alone or along with pSG5–ERa (50 ng) or pSG5–ERa (50 ng) plus pCI–
PNRC (WT), pCI–PNRC/del NR box ( NR box), or pCI–PNRC/del SH3
motif ( SH3 motif) (1 mg each). Four hours after transfection, cells were
cultured in the presence of 10 nM 17-b-estradiol (E2) or DMSO (the vehicle
control) for additional 20 h. Twenty-four hours after transfection, cells were
harvested, lysed and the luciferase activities in the cell lysate from triplicate
wells were measured as described in the Materials and Methods, and
expressed as mean ± SD of three independent assays. (C) Western blot
analysis. Twenty-five microgram extract prepared from non-transfected HeLa
cells (HeLa) or from pCI–PNRC/del NR box (PNRC   NR box), pCI–PNRC/
del SH3 (PNRC   SH3), or pCI–PNRC WT (PNRCwt) transfected HeLa
cells was subjected to 10% SDS–PAGE and western blot analysis using
PNRC antiserum and b-actin antibody, respectively, as described in the
Materials and Methods. (D) Cellular localization of wild-type PNRC and
PNRC/del SH3 motif. HeLa cells in 6-well dish were transfected with
pEGFP, pEGFP-PNRCwt or pEGFP–PNRC/del SH3 motif. Twenty-four
hours after transfection, the images of the expressed fluorescent proteins in
transfected HeLa cells were taken using a fluorescence microscope. The
images shown are the merged images of bright field images (whole cells) and
green fluorescence image (expressed fluorescent proteins).
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transfected into HeLa cells. The cellular localizations of
EGFP (control), EGFP–PNRC, and EGFP–PNRC/del SH3
motif in the transfected HeLa cells were examined using
an inverted ﬂuorescence microscope. As shown in
Figure 3D, both EGFP–PNRC/WT and EGFP–PNRC/del
SH3 motif were localized in the nuclei of HeLa cells
while EGFP protein was present in the cytoplasm.
Importance of the flanking sequences of SH3-binding
motif in the interaction between PNRC and ERa
The second member of PNRC coactivator family, PNRC2,
was also identiﬁed in the same yeast two-hybrid screening
of a human mammary gland cDNA library through its inter-
action with SF1. The amino acid region 85–130 of PNRC2
contains a proline-rich 23-amino acid region (amino acids
99–105) and an NR box-like sequence (amino acids
132–136), with 96% amino acid sequence identity between
PNRC and PNRC2. The locations of the SH3-binding motif
and NR-box in PNRC and PNRC2 molecules are shown in
Figure 4A. The results from our previous deletion and muta-
genesis study demonstrated that SH3-binding motif in the
amino acids 85–139 was very important for PNRC2 to inter-
act with nuclear receptors including SF1, ERa and ERRa1.
Intriguingly, however, the NR box-containing sequence in
PNRC2 is differentially required for its interaction with dif-
ferent nuclear receptors (6). Our previous results suggest
that the sequences between the SH3-binding motif and NR
box in PNRC and PNRC2 may have an important impact
as to how these proteins interact with nuclear receptors.
Therefore, the importance of the sequences ﬂanking SH3-
binding motif and NR box for the interaction of PNRC and
ERa was examined by deletion mutagenesis or by replace-
ment of the interested PNRC region with corresponding
region of PNRC2.
To examine the importance of the amino acid region
270–284 in the interaction, it was either deleted from
PNRC270–327 fragment (in construct pACT2–PNRC285–327)
or replaced with the corresponding amino acid region
85–98 of PNRC2 (in construct pACT2–PNRC285–98–
PNRC285–327). As shown in Figure 4B, three fragments,
PNRC270–327, PNRC285–327 and PNRC285–98–PNRC285–327
interacted with ERa/HBD to similar degrees. These results
demonstrated that deletion or replacement of amino acids
270–284 in the PNRC270–327 content did not affect its interac-
tion with ERa/HBD, suggesting that the region 270–284 is
not essential for the interaction.
The importance of sequences between SH3-binding motif
and NR box of PNRC, amino acids 292–318, was also exam-
ined by a combination of deletion and replacement mutagene-
sis and yeast two-hybrid assays. As shown in Figure 4C,
deletion of amino acids 292–318 from PNRC270–327 fragment
totally abolished the interaction of PNRC and ERa. Replace-
ment of this region with corresponding PNRC2 sequence,
amino acids 106–131, restored ERa-interacting ability of
PNRC. Sequence comparison of amino acid residues between
PNRC292–318 and PNRC2106–131 showed a high homology.
These results indicate that the amino acid sequences from
292 to 318, are critical for the interaction between PNRC
and ERa/HBD. To further investigate whether this region
 
Figure 4. Importance of the flanking sequences of SH3-binding motif in the
interaction between PNRC and ERa.( A) Diagram of the residue location of
SH3-binding motif and NR box sequence on PNRC and PNRC2 molecules.
(B) PNRC270–284 region is not required for the PNRC–ERa interaction. The
yeast expression plasmids for ADGal4 and PNRC270–327, PNRC285–327 or
PNRC285–98–PNRC285–327 fusion protein were constructed as described in
the Materials and Methods. The procedures for yeast transformation and
b-Galactosidase activity measurement are the same as described in Figure 1A.
(C) The sequences between NR box and SH3-binding motif is critical for the
PNRC–ERa interaction. The construction of the plasmids used in this figure
was described in the Materials and Methods. The procedures for yeast two-
hybrid assays are the same as described in (B). (D) the sequences between NR
box and SH3-binding motif is required for the PNRC coactivator function.
The procedures for transient transfection and luciferase assay were the same
as described in Figure 3B. ERa, pSG5-ERa, 50 ng; PNRCwt, pCI–PNRC,
1.0 mg; PNRC292–318, pCI–PNRC/del292–318, 1.0 mg.
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transactivation function, a mammalian expression plasmid
for PNRC/del292–318, pCI–PNRC/del292–318, was prepared
and transfected into HeLa cells. The ability of this mutant
to potentiate the transcription mediated by ERa was exam-
ined and compared with that of wild-type PNRC. As
shown in Figure 4D, deletion of amino acid region 292–
318 from PNRC abolished its coactivator activity, demon-
strating the requirement of this region in PNRC coactivation
function.
Both AF1 and LBD domain of human
ERa interacts with PNRC
Asmostofcoactivators,PNRCandPNRC2interactwithERa/
HBD domain in a ligand- and AF2-domain dependent manner
(5). To determine whether the interaction between PNRC and
ERa is also involved in the other domains of ERa, i.e. the AF1
domain (amino acids 1–185), DNA-binding domain (DBD,
amino acids 186–251), hinge region (amino acids 252–355),
CTE (C-terminal Extension) domain (amino acids 252–288),
hormone-binding domains (HBDs, amino acids 356–549 or
297–554 or 274–595) and F domain (amino acids 550–595),
as shown in the diagram of Figure 5A, of human ERa were
expressed as DBDGal4 fusion proteins and examined for their
interaction with PNRC270–327 fragment in yeast two-hybrid
assays. As shown in Figure 5B, in addition to ERa/HBD that
interacts with PNRC270–327 in a ligand-dependent manner,
AF1 region also interacts with PNRC270–327. However, this
interaction is much weaker and is in a ligand-independent
manner. We noticed that in the presence of estradiol, PNRC
also interacted weakly with ERa252–355. No interaction was
detected between PNRC and other domains of ERa, including
hingeregion,CTEandFdomains.Additionalexperimentswill
be performed to explore the interaction between ERa/AF1 and
PNRC in detail.
PNRC is a coactivator of both AF1
and AF2 domains of ERa
Nuclear receptors contain two transcription activation func-
tions, AF1 in the NTD and AF2 in the HBD. PNRC was pre-
viously demonstrated to interact with ERa and function as
ERa coactivator in a ligand and AF2-dependent manner. In
this study, PNRC was found to interact with both AF1
domain and HBD of ERa. Therefore, the capacity of PNRC
in stimulating the two activation functions of ERa was ana-
lyzed in transient transfection experiments. Full-length PNRC
expression plasmid was cotransfected in HeLa cells with
expression vectors for the full-length ERa or for the deletion
constructs for ERa along with a (ERE)3_luciferase reporter,
pGL3-(ERE)3_Luciferase. The deletion constructs AF1/
DBD (amino acids 1–251) and DBD/HBD (amino acids
185–595) each retains the ERa DNA-binding domain but
is missing the HBD and the N-terminal domain that
contains AF1 function, respectively. The transfected cells
were exposed to either 100 nM estradiol or vehicle control,
DMSO. As shown in Figure 5C, the luciferase activity in
the cells transfected with wild-type ERa was enhanced
2.5-fold by the coexpression of PNRC in the presence of
estradiol, not in the presence of DMSO. In addition, both
AF1/DBD and DBD/HBD fragment of ERa slightly activated
the luciferase gene transcription, and coexpression of
PNRC enhanced the reporter activity mediated by ERa/
AF1–DBD in a ligand-independent manner and the reporter
activity mediated by ERa/DBD–HBD in a ligand-dependent
manner. Together, this study demonstrated that PNRC
interacts with both AF1 and HBD of ERa and functions
as coactivator for both AF1 and AF2 transactivation
functions.
Important residues in ERa/LBD for the
interaction between PNRC and ERa
Site-directed mutagenesis in combination with transient
transfection and yeast two-hybrid assays was employed to
examine the importance of residues in the HBD of human
ERa in the interaction for PNRC. Our mutagenesis design
was based on a crystal structure of the ERa HBD complexed
with diethylstilbestrol and an NR box-containing 13-amino
acid peptide derived from GRIP1 coactivator (10). The inter-
action surface in the ER consists of 16-amino acid residues
from helices 3, 4, 5 and 12: L354, V355, I358, A361, K362
(helix 3); L372 (helix 3, 4 turn); F367, V368 (helix 4); Q375,
V376, L379 E380 (helix 5); and D538, L539, E542, M543
(helix 12). ER mutants including I358R, K362A, V376R,
L539R and E542K have been reported to completely lose
the ability to interact with coactivator GRIP1 (10,11). Since
PNRC interacts with ERa mainly through SH3-binding
motif, not NR box sequence, one would expect a different
intersurface between ERa and PNRC from that between
ERa and P160 coactivator such as GRIP1. Therefore, the
same set of ER mutations, including I358R, K362A,
V376R, L539R and E542K were prepared and examined
for their transactivation function by transient transfection.
As shown in Figure 6A, the transactivation activities of all
the mutated ERa were much lower than that of the wild-
type ERa, except that V376R still retained 50% activity of
wild-type ERa. Cotransfection with PNRC expression plas-
mid enhanced the transactivation activities of the wild-type
ERa and ERa/V376R by 2- and 5-fold, respectively, but
not the activities of other ERa mutants, including I358R,
K362A, L539R and E542K (Figure 6A). The changes in
the transactivation activities of those mutated ERa are indeed
the consequences of mutation, not due to the differences in
the expression levels, as demonstrated by western blot
using ERa antibody (Figure 6B). To further determine
whether these speciﬁc ERa mutants also cause loss of inter-
action with PNRC, as all of these mutants were found to lose
the interaction with GRIP1 (10), the wild-type ERa/HBDs
and ERa/HBD mutants carrying each of above ﬁve speciﬁc
mutations were expressed as fusion protein with DBDGal4,
and their abilities to interact with PNRC were examined in
yeast two-hybrid assays. The wild-type ERa/HBD and
ERa/HBD/V376R were found to interact with PNRC
(Figure 6B) and PNRC2 (data not shown). No interaction
was detected between PNRC and ERa/HBD/I358R, ERa/
HBD/K362A, ERa/HBD/L539R or ERa/HBD/E542K
(Figure 6B). These results are in agreement with the results
obtained from our transactivation function analysis. The res-
idue V376 was found to be in the ERa–GRIP1/NR box inter-
action surface and V376R was designed to perturb the
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Figure 5. PNRC interacts with AF1 and LBD domains of human ERa and functions as coactivator for both transactivation domains. (A) A schematic diagram
of human ERa domains and the representation of the various ERa deletion constructs prepared and used. (B) Yeast strain Y187 was cotransformed with pACT2
(for the expression of ADGal4) or pACT2–PNRC270–327 (for the expression of ADGal4–PNRC270–327 fusion protein) and an yeast expression plasmid for the fusion
proteins of DBDGal4 and various deletion mutants of ERa as indicated. The yeast transformants bearing both plasmids were cultured in the absence (DMSO) or
presence of 10 nM E2. b-Galactosidase activities were determined and expressed as the mean (units) ± SD of three independent colonies. (C) HeLa cells were
transfected with pGL3 (ERE)3_SV40_Luciferase reporter (0.25 mg) alone or along with pSG5–ERa wt, pSG5–hERa1–251, or pSG5–hERa185–595 (50 ng each)
and with (+PNRC) or without pSG5–PNRC (1.0 mg) ( PNRC). Four hours after transfection, cells were cultured in the absence (DMSO, vehicle control)
presence of 10 nM E2 for additional 20 h. Twenty-four hours after transfection, cells were harvested, lysed and the luciferase activities in the cell lysate from
triplicate wells were measured as described in the Materials and Methods, and expressed as mean ± SD of three independent assays.
Nucleic Acids Research, 2006, Vol. 34, No. 20 5983nonpolar character of the ﬂoor of the binding groove. V376R
mutant was found to lose its interaction with GRIP1 (10) and
therefore the transactivation function (11). However, in our
study, ERa/HBD/V376R still interacts with PNRC or
PNRC2, with similar afﬁnity as the wild-type ERa/HBD
and the transactivation activity of ERa/V376R mutant was
enhanced 5-fold by PNRC while GRIP1 has no effect on
the transactivation function of this mutant, implying that
the PNRC–ERa interaction interface is not exactly identical
to that of GRIP1–ERa interaction.
DISCUSSION
Results from this and other laboratories (5,7,8) have demon-
strated that PNRC acts as a coactivator for a number of
nuclear receptors, and experiments from this laboratory (5)
have found that PNRC is a novel coactivator in that its
proline-rich SH3-binding motif is important for the interac-
tion with nuclear receptors. In this study, we have carefully
characterized the structural determinants of the interaction
between PNRC and ERa, as well as the functional conse-
quences of their interaction. Speciﬁcally, we showed that
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region 270–327. There is one NR box-like sequence, LKTLL
(amino acids 319–323), at the very end of the C-terminus in
PNRC. It is well known that most of the coactivators interact
with AF2 in LBD (ligand-binding domain) of many nuclear
receptors via conserved, helical LXXLL motifs, named NR
box (3). This sequence forms part of an amphipathic a-
helix, which binds in a conserved hydrophobic cleft on the
surface of liganded LBDs. However, the NR box was found
to be nonessential for ERa-interaction although it may be
required for higher afﬁnity binding between PNRC and
ERa. The amino acid region 270–327 of PNRC contains a
23-amino acid region with 100% identity between PNRC
and PNRC2. The SH3-binding motif in the amino acid region
278–300 was found to be essential for PNRC to interact with
ERa. The importance of NR box motif and SH3-binding
motif on the coactivation function of PNRC on ERa’s trans-
activation activity was further compared. In agreement with
the observation for the ERa interaction, the NR box motif
is not required for PNRC to function as a coactivator for
ERa while the SH3-binding motif is critical for PNRC to
enhance the transcription mediated by ERa. Thus, PNRC is
a unique coactivator that interacts with nuclear receptors
through its proline-rich SH3-binding motif which is both
structurally and functionally important. The importance of
the sequences ﬂanking SH3-binding motif and NR box was
also investigated by deletion and/or insertion mutagenesis.
The 50 ﬂanking sequences of SH3-binding motif, amino
acids 270–284, was found to be not required for the
PNRC–ERa interaction, while the residues between NR
box and SH3-binding motif, from 292 to 318, are critical
for the interaction between PNRC and ERa/HBD as well as
its coactivator activity.
PNRC-interacting domain(s) on ERa was also mapped in
this study. We found that PNRC interacts with both AF1
and LBD of ERa, and functions as a coactivator for both
AF1 and AF2 transactivation functions (Figure 5C). Further-
more, the interaction between PNRC and ERa/HBD and the
coactivation function of PNRC on the transcription mediated
by ERa/HBD were found to be ligand dependent, while its
interaction with ERa/AF1 and its coactivation function
towards ERa/AF1-mediated transcription was found to be
ligand independent (Figure 5B and C). This property of
PNRC is similar to that of some p160 coactivators. In addi-
tion to the interaction, in a ligand-dependent manner, with
the AF2 domain of NRs through the LXXLL motif, the
C-terminal region of the p160 coactivators is also able to
interact with the AF1 domain of some NRs, and then enhance
the AF1 activities of those NRs in the absence of ligands. For
example, SRC1 has been shown to interact with both the
N-terminal A/B or AF1-containing domain and the C-
terminal D/E or AF2-containing domain of PR, and hence
to enhance the transcriptional activity of AF1 and AF2 of
PR in a cooperative manner (20). SRC1 was also found to
interact with AF1 of AR via a conserved, glutamine-rich
region (21) and to interact with AB domain of ERa and
potential ERa’s AF1 transcription function (22). TIF2/
GRIP1 was shown to be able to interact with both AF1 and
AF2 domain of the two ERs, ERa and ERb, and the concomi-
tant interaction of TIF2/GRIP1 with both AFs results in syn-
ergistic activation of transcription mediated by ERs (23).
PNRC2, a closely related coactivator to PNRC, was also
identiﬁed as activation function-1 (AF1) cofactor of the
orphan nuclear receptor ERRg from a human brain cDNA
phage display system with the N-terminal domain of
ERRg2 as bait (7). In their transfection experiments, A/B
region of ERRg2, which encodes the AF-1 domain, was nec-
essary for optimal PNRC2-dependent transactivation.
Since PNRC interacts with ERa mainly through SH3-
binding motif, not NR box sequence, we expected to see an
interface between ERa and PNRC which is different from
that between ERa and p160 coactivator such as GRIP1.
Therefore, the same set of ER mutations, including I358R,
K362A, V376R, L539R and E542K were prepared and exam-
ined for their transactivation function by transient transfec-
tion. ERa/HBD/V376R, which has been shown to lose its
ability to interact with GRIP1 (10), was shown to still interact
with PNRC or PNRC2, with similar afﬁnity as wild-type
ERa/HBD (Figure 6B). Consequently, the full-length ERa
carrying V376R mutation retains 50% of transactivation
activity of wild type. Furthermore, the transactivation activity
of ERa/V376R mutant is enhanced 5-fold by the cotransfec-
tion of PNRC but not be affected by GRIP1. These results
imply that the PNRC–ERa interaction interface may be dif-
ferent from that of GRIP1–ERa interaction. The physiolo-
gical signiﬁcance of this ﬁnding is not totally known at the
present time. However, one could speculate that this would
allow the formation of more active coactivator complexes
that include PNRC and other coactivators. Furthermore, it
is possible that the structural requirements for the interaction
of PNRC and nuclear receptors such as ERa would provide
some levels of selectivity of nuclear receptors that interact
with PNRC. As indicated by Albers et al. (8), PNRC (and
PNRC2) only interacts with few nuclear receptors among
those tested.
In conclusion, we believe that this is a thorough study to
determine the molecular features of the interaction between
PNRC and ERa. The results presented in this paper demon-
strate that PNRC (and PNRC2) is an unusual coactivator
that interacts with nuclear receptors such as estrogen receptor
in a novel manner. Since results from this and other laborat-
ories indicate that PNRC and PNRC2 are more general cofac-
tors for nuclear receptor than previously appreciated, it is
essential to understand how they interact and regulate the
activity of nuclear receptors.
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